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INTRODUCTION 
Headache is the most common cause of referral to the 
doctor and the incidence probability of a headache during 
life for women and men were 95% and 90%, respectively. 
Among the causes of headache, migraine is one of the most 
common headache that affects 18.2% of women and 6.5% 
of men aged 12-80 years.1 Migraines usually start in the 
second decade of life and 90% of patients experience the 
first migraine attack until age 40.2 Every migraine attack 
takes about 4-7 hours and usually its severity is so severe 
that it interferes with people’s daily activities, 
occupational and individual performance.1 
Migraines are a common disabling disorder. People with 
migraine often suffer from severe headaches. These 
headaches are usually associated with autonom symptoms. 
Frequency, duration and severity of migraine attacks vary 
from person to person and most of migraine patients 
experience courses of temporary disability in migraine 
attacks. These attacks affect individual activity and quality 
of life. Therefore, attention to the treatment and prevention 
of migraine is very important. Migraine may be a 
progressive disorder that in the absence of treatment, turns 
from episodic to chronic state while aggressive treatment 
may prevent this progress.3 Treatment of migraines is 
divided into symptomatic and preventative types and 
patients with more than 3-4 attacks per month or severity 
causing a patient's disability require prophylaxis.4,5 
Preventive treatments included medication, dietary 
changes , physical therapy and prevention of psychological 
stress and preventing exacerbating factors.6 The most 
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effective preventive drugs for migraine attacks are : Beta 
receptor antagonists , anticonvulsants, antidepressants and 
calcium channel blockers.7 Sodium Valproate is an anti- 
seizure drug. This drug was approved in the year 2000 by 
FDA for the prevention of migraines. Side effects of 
sodium valproate included tremor, obesity, hair loss and 
fetal complications during pregnancy.8 Levetiracetam is 
another anticonvulsant drug approved by the FDA to treat 
seizures and its mechanism not known yet.9 But in several 
studies, its effect on chronic headaches has been reported. 
Side effects of Levetiracetam included insomnia, 
irritability, dizziness and blurred vision. This drug had 
renal excretion and a half life of 7 to 8 hours.10 The aim of 
this study was to compare the effect of Levetiracetam (L) 
and sodium Valproate (SV) in the prevention of migraine.  
METHODS 
Study design and patients 
We conducted a prospective, randomized clinical trial 
study. A total of 86 patients were randomized to receive 
levetiracetam 500mg/d (n= 42) and valproate 500mg/d 
(n= 44). The patients were evaluated for treatment 
efficacy after 3 months. Efficacy was assessed as a more 
than 50% decrease in headache frequency.  
Inclusion criteria 
Patients with a history of migraine, the number of migraine 
attacks from 4 to 15 times in a month, failure of 
prophylactic treatment with one or more migraine 
prevention drugs and age 16 to 65 years old were included 
in the study.  
Exclusion criteria 
Patients with a history of sodium valproate and 
levetiracetam use, breast feeding duration, had underlying 
illnesses such as liver and kidney failure, drug and alcohol 
use, smoking, the use of sedative medications and pregnant 
women were excluded from the study.  
Data collection 
Demographics data were completed at the start of the study 
and completed MIDAS form. MIDAS questions indicate 
the days of absence at work, days of reduced work 
efficiency by more than 50%, days of inability to do 
homework and days of non attendance at social and 
recreational activities and family meetings due to migraine 
in the past 3 months. The score and rank of MIDAS, 
frequency and severity of attacks determined by the patient 
himself. During the study, the selected individuals could 
be divested from the study. patients were visited 3 times in 
3 months and in each visit questions related to the MIDAS 
factors monthly and the rate of use of acute drugs for acute 
headache attacks during the past month and the side effects 
of drugs recorded in a checklist. The medications were 
prescribed to the patient to contact the doctor if they have 
a contamination. Patients with intolerance to the drug were 
divested from the study at each stage. Patients were visited 
monthly and the efficacy of treatment based on the 
frequency of migraine attacks per month, the change in the 
MIDAS score and the severity of headache were recorded 
by the patient's own scoring scale with a headache 
intensity of 0 to 10 and also the reduction in the use of 
acute treatment for the attacks was measured. All patients 
advise on avoiding lack of sleep and sleeping and avoiding 
factors such as (high consumption of caffeine, long term 
hunger, noisy environments, alcohol and smoking) which 
worsen their migraine headache.  
This study was registered with code of ethics 
IR.ARUMS.REC.1396.133 and IRCT registration number 
IRCT20171011036717N1. All patients completed the 
consent form.  
Statistical analysis  
Collected data were analyzed by SPSS version 22 using 
descriptive and analytical statistical methods. The level of 
significance was less than 0.05.  
RESULTS 
There was no significant difference between two groups in 
terms of age, sex, diet, education level, history of 
headache, headache frequency, headache acute drug use 
and MIDAS (Table 1). Of the levetiracetam group, 9 
(21%) were male and 33 (79%) were female of sodium 
valproate group, 8 (18%) were male and 36 (82%) were 
female. The average age of group Sodium valproate was 
35.14±3.7 and levetiracetam group was 36.33±6.6 and the 
mean age of the all patients was 35.91±6.9. This difference 
wasn’t significant. The duration of migraine was 
9.95±5.93 in group Sodium valproate and 10.95±5.43 
years in group levetiracetam and 10.47±6.63 years in all 
group. This difference was not significant (Table 1).  
The headache frequency in group Sodium valproate was 
4.6±1.75 and in group levetiracetam was 2.6±1.43 which 
was not statistically significant in the baseline. After 3 
months the headache frequency was 3.9±1.18 and 
2.29±0.88 in groups Sodium valproate and levetiracetam, 
respectively which was statistically significant difference 
(P=0.0001) and indicates a better levetiracetam effect.  
The duration of migraine attack was 16.63±6.8 in group 
Sodium valproate and 14.21±4.5 in group levetiracetam 
respectively that it was not statistically significant. After 3 
months of treatment the duration of migraine attack was 
11.4±6.9 and 10.5±2.5 in the Sodium valproate and 
levetiracetam groups respectively and the difference was 
statistically significant (P=0.0001). 
The severity of headache in group Sodium valproate was 
7.67±1.64 and in the group levetiracetam was 7.64±1.67 
which wasn’t statistically significant. After 3 months of 
treatment, the duration of headache severity in the Sodium 
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valproate and levetiracetam groups was 4/62±2/6 and 
4/33±2/24 in groups Sodium valproate and levetiracetam 
respectively and the difference was statistically significant 
(P=0.004). 
The mean of MIDAS score in group Sodium valproate was 
2.67±1.19 and in group levetiracetam was 2.64±1.19 and 
wasn’t statistically significant difference. After 3 months 
of treatment, the average MIDAS score in the Sodium 
valproate and levetiracetam groups was 1.27±1.11 and 
9.15 ± 0.81 respectively which was statistically significant 
difference (P value = 0.001).  
Table 1: Comparison of frequency, duration, intensity 
of headache and MIDAS score in two groups before 
prescribing the drug (at baseline). 
P 
value 
SD mean group variables 
0.27 
1.75 6.4 
Sodium 
valproate 
Headache 
frequency 
1.43 6.2 levetiracetam 
0.36 
6.8 16.63 
Sodium 
valproate 
Duration of 
headache 
5.4 14.21 levetiracetam 
0.94 
1.64 7.67 
Sodium 
valproate 
Headache 
severity 
1.67 7.64 levetiracetam 
0.91 
1.09 2.67 
Sodium 
valproate 
MIDAS 
score 
1.08 2.64 levetiracetam 
0.7 
5.4 9.95 
Sodium 
valproate 
The duration 
of migraine 
 5.6 10.95 levetiracetam 
0.5 
7.3 35.14 
Sodium 
valproate Age  
6.6 36.32 levetiracetam 
Table 2: Comparison of frequency, duration and 
severity of headache and MIDAS score after the 
administration of the drug. 
P 
value 
SD Mean Group Variables 
0.001 
1.18 3.9 
Sodium 
valproate 
Headache 
frequency 
0.88 2.29 Levetiracetam 
0.001 
6.09 11.4 
Sodium 
valproate 
Duration 
of 
headache 5.2 10 Levetiracetam 
0.001 
2.16 4.62 
Sodium 
valproate 
Headache 
severity 
2.24 4.33 Levetiracetam 
0.001 
0.45 1.27 
Sodium 
valproate 
MIDAS 
score 
0.36 1.15 Levetiracetam 
 
DISCUSSION 
Although the efficacy of sodium valproate in preventing 
migraine has been confirmed in valid clinical studies and 
this drug is one of the approved drugs in the prevention of 
migraine. But long term use of this medication due to its 
side effects (depression, muscle weakness, tremor, ataxia, 
headache, insomnia, drowsiness, drowsiness, blurred 
vision, nausea, vomiting, indigestion, diarrhea, abdominal 
cramps, constipation, increased Appetite, anorexia, 
hepatitis, weight gain, alopecia, multiple form erythema, 
flu like syndrome, itching, rash, Stevens Johnson 
syndrome) can be limited in future.11  
This study is in line with previous studies that reported the 
efficacy of levetiracetam in preventing migraines. Virgilio 
Gallai et al, in a study reported a reduction of 50% in the 
number of headache attacks after receiving levetiracetam 
and showed that the number of migraine attacks was 
significantly reduced, which was in line with the result of 
our study which showed high efficacy of levetiracetam.12 
In this study, the dosage of levetiracetam was 500 mg per 
day that no adverse drug effect was observed in any of the 
patients it may be due to low dose medication. Sdeghian in 
a study in the Tehran showed that the levetiracetam had a 
50% reduction in the number of migraine attacks after 
receiving levetiracetam and has a comparable effect with 
other antiepileptic drugs such as sodium valproate which 
was in line in this study results.13  
M. Homam and et al, in a study in Mashhad showed that 
the side effects of levetiracetam was lower than sodium 
valproate.14 In the present study, both drugs had significant 
effects in reducing attacks and severity of migraine attacks 
of course in this study the effect of levetiracetam on the 
reduction of headache frequency was greater than that of 
sodium valproate. Stewart and et al reported a 50% 
decrease in the number of headache attacks after 
levetiracetam receiving and levetiracetam did not have any 
side effects and levetiracetam was considered as a new 
preventive treatment for the treatment of migraine without 
aura which was in line with the results of this study.15 
Verma and et al reported a reduction 50% in the migraine 
attacks after levetiracetam treatment which was in line 
with our study results.16  
CONCLUSION 
Results showed that both of levetiracetam and sodium 
valproate were effective in reducing the frequency, 
severity and duration of headache and MIDAS score. Of 
course, the reduction of headache frequency in 
levetiracetam group was significantly higher than sodium 
valproate group. It seems that the levetiracetam in 
preventing migraine headaches was better than sodium 
valproate and also due to less complications of 
levetiracetam it can be used as an alternative medicine in 
future.  
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